

## **SYSTEMATIC REVIEW AND META ANALYSIS**

### **Prevalence, clinical characteristics and treatment outcomes of HIV and SARS-CoV-2 co-infection: a systematic review and meta-analysis**

#### **AUTHORS**

Joseph Baruch Baluku<sup>1,2,†</sup>, Ronald Olum<sup>3</sup>, Curthbert Agolor<sup>1</sup>, Josephine Nakakande<sup>1</sup>, Laura Russell<sup>4</sup>, Felix Bongomin<sup>5</sup>, Jane Nakawesi<sup>1</sup>

#### **INSTITUTIONS OF AFFILIATION**

<sup>1</sup>Mildmay Uganda, Wakiso, Uganda

<sup>2</sup>Division of Pulmonology, Mulago National Referral Hospital, Kampala, Uganda

<sup>3</sup>School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda

<sup>4</sup>Manchester University NHS Foundation Trust, Manchester, United Kingdom

<sup>5</sup>Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda.

†Corresponding author,

P.O Box 24985, Kampala, Uganda

joseph.baluku@mildmay.or.ug, bbjoe18@gmail.com

+256706327972

**Abstract word count:** 291

**Main Text word count:** 1,830

## ABSTRACT

**Objectives:** To determine the prevalence, clinical characteristics and outcomes of HIV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection.

**Methods:** We searched Medline, Embase, Cochrane and Web of Science databases and grey literature for studies reporting epidemiological and clinical data of patients with HIV and SARS-CoV-2 co-infection. Eligible studies were all observational or interventional studies and commentaries in English language that reported patient data on HIV/SARS-CoV-2 co-infection. We used random effect meta-analysis to determine the pooled prevalence and mortality.

**Results:** Of the 17 eligible studies, there were 3 retrospective cohorts, 1 survey, 5 case series, 7 case reports and 1 commentary that reported on a total of 146 HIV infected individuals. The pooled prevalence of HIV among individuals with SARS-CoV-2 infection was 1.0% (95% CI: 0.0 – 3.0,  $I^2 = 79.3%$ ,  $p=0.01$ ), whereas the prevalence of SARS-CoV-2 among HIV patients was 0.68% (95% CI: 0.34 – 1.34). There were 110 (83.8%) HIV/ SARS-CoV-2 co-infected males, and the age (range) of the co-infected was 30 – 60 years. A total of 129 (97.0%) were anti-retroviral therapy experienced, and 113 (85.6%) had a suppressed HIV viral load. The CD4 count (range) was 298 – 670 cells/mm<sup>3</sup> ( $n = 107$ ). The commonest symptoms were fever (73.5%,  $n=75$ ) and cough (57.8%,  $n = 59$ ). Sixty-two (65.3%) patients had at least one other comorbid condition, of which hypertension (26.4%,  $n = 38$ ) was the commonest. Chest radiological imaging abnormalities were found in 46 (54.1%) cases. Twenty-eight cases (56.0%) were reported as mild. Recovery occurred in 120 (88.9%) cases, and the pooled mortality was 9% (95% CI: 3.0 – 15.0,  $I^2 = 25.6%$ ,  $p =0.24$ ).

**Conclusion:** The prevalence of HIV/SARS-CoV-2 co-infection was low. The clinical characteristics and outcomes of HIV/SARS-CoV-2 co-infection are comparable to those reported among HIV negative SARS-CoV-2 cases.

**Key words:** HIV, COVID -19, clinical manifestations, outcomes, corona virus, AIDS, SARS-CoV-2, co-infection

## **BACKGROUND**

Over 5.5 million cases of coronavirus disease of 2019 (COVID-19) – caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – have been reported globally with approximately 350,000 deaths as of 28<sup>th</sup> May 2020 (1). Pre-existing conditions such as respiratory disease, hypertension and cardiovascular disease have been linked to severe forms of COVID – 19 (2). Epidemiological and clinical implications of HIV/SARS-CoV-2 co-infection are unknown for the 38 million people living with HIV (PLHIV) globally (3). SARS-CoV-2 infection has been reported to cause immune dysregulation that is characterised by low CD4 counts and elevated interleukin-6 (IL – 6), both of which can theoretically increase the risk of superimposed opportunistic infections and death among PLHIV (4). Moreover, PLHIV have a high prevalence of the pre-existing conditions that are associated with poor outcomes of COVID – 19 (5). There is need for synthesis of the currently available reports on HIV/SARS-CoV-2 co-infection to guide HIV care programs and clinical teams in the management of PLHIV, especially in resource limited settings where 70% of PLHIV are found.

## **OBJECTIVES**

The aim of this systematic review and meta-analysis was to determine the prevalence, clinical characteristics and outcomes of HIV/SARS-CoV-2 co-infection.

## **MATERIALS AND METHODS**

### **Data sources, study eligibility and selection**

This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (6). We searched for clinical studies from Medline, Embase, Cochrane and Web of Science databases published in English from

inception to May 22 2020. Duplicates were automatically removed using HDAS (<https://hdas.nice.org.uk/>). The search strategy is shown in appendix 1. There were no unique results on Cochrane or Web of Science databases. We also manually searched for additional sources from reference lists of eligible publications and pre-print repositories. Studies were reviewed by title and abstract by LR and JBB. Eligible studies were all observational or interventional studies and commentaries that reported data on patients with HIV and SARS-CoV-2 co-infection. For the meta-analysis of mortality, studies that reported data on less than 4 subjects were excluded. The study flow diagram is shown in figure 1.

### **Data extraction, study outcomes and analysis**

From eligible studies, JBB and OR extracted data on study design, year of publication, country of origin and number of participants. We further extracted aggregated and/or individual patient data on prevalence of HIV among SARS-CoV-2 cases, prevalence of SARS-CoV-2 among PLHIV, demographic characteristics of HIV/SARS-CoV-2 co-infected patients, presenting complaints, other comorbid conditions, radiological chest imaging findings, disease severity, drugs used in management and treatment outcomes. Disagreements were resolved by a third reviewer (FB). The study outcomes were the prevalence of HIV/SARS-CoV-2 co-infection, the proportions of clinical characteristics and treatment outcomes of HIV/SARS-CoV-2 co-infection. We used random effect meta-analysis to determine pooled prevalence and mortality. Analysis was performed using STATA 16.0. Heterogeneity across studies was assessed using Q statistics and significance was set at  $p < 0.05$  at the 95% confidence interval (CI).

## **RESULTS AND DISCUSSION**

### **Study characteristics**

As shown in table 1, 17 studies were included in the systematic review, of which 3 (7–9) and 6 (7,8,10–13) were included in the prevalence and mortality meta-analysis respectively. All studies were published in the year 2020. There were 3 retrospective cohorts, 1 survey, 5

case series, 6 case reports and 1 commentary. Of all studies, only 2 case reports (14,15) were from sub-Saharan Africa where 70% of HIV patients are found (16). While this may limit the generalizability of the findings of this review, it raises an urgent need for reports on HIV/SARS-CoV-2 co-infection from this region. The total number of HIV/SARS-CoV-2 co-infected patients reported on was 146.

### **Prevalence of HIV/SARS-CoV-2 co-infection**

Three studies (7–9) reported the proportion of HIV infected individuals among a total of 3,438 SARS-CoV-2 cases. The pooled prevalence of HIV among SARS-CoV-2 was 1.0% (95% confidence interval (CI): 0.0 – 3.0,  $I^2 = 79.3\%$ ,  $p=0.01$ ) as shown in the forest plot in figure 2. There was significant heterogeneity of the studies and the estimate should be interpreted cautiously. Guo, *et al.*, (13) reported a prevalence of SARS-Cov-2 of 0.68% (95% CI: 0.34 – 1.34) among 1,174 HIV patients. Gervasoni *et al.*, (10) also reported to have identified 47 SARS-CoV-2 infected individuals from a database of “nearly” 6,000 PLHIV, thus giving an approximate prevalence of 0.78% (95% CI: 0.59 – 1.04). The prevalence of SARS-CoV-2 among PLHIV is therefore comparable to the 0.6 – 0.8% SARS-CoV-2 prevalence reported in the general population (17).

### **Clinical features of HIV/SARS-CoV-2 co-infection**

#### **Demographic characteristics**

Of 133 patients, 112 (84.2%) were male whereas 2 were transgender. One study did not report the sex of PLHIV (8). Five participants were men who have sex with men (9,18). The higher proportion of males with COVID-19 could partly be explained by lower activity of innate and adaptive immune responses against viruses compared to women (19). The mean/median age (range) was 30 – 60 years (7,10,11,13). It appears that the majority of PLHIV in these studies were <65 years, which would otherwise increase the risk for poor outcomes (20). Paediatric HIV/SARS-CoV-2 co-infection was not reported, and therefore an area for further investigation.

## **Symptoms and other comorbid conditions**

The commonest symptoms were fever (73.8%, n=76) and cough (57.3%, n = 59). Four studies (7,8,13,21) did not report symptoms for 43 patients. The duration (range) of symptoms before presentation was 1 – 14 days (n =16) (9,12,14,18,22–25). Fever and cough have been consistently reported to be the commonest symptoms of COVID – 19 and our finding is in agreement with this observation (26). Sixty two (65.3%) patients had at least one other comorbid condition (9–11,18,22,23,27,28). This is expectedly higher than the 25.1% reported among HIV negative individuals in China (29). Among the counts of comorbid conditions, the commonest were hypertension, hyperlipidaemia and diabetes mellitus. Similarly, hypertension (21.1%) and diabetes (9.7%) are the most prevalent comorbid conditions among HIV negative patients with COVID – 19 (2). Hyperlipidaemia has not been a key comorbidity in previous reports on COVID -19. It should however be expected among PLHIV since their lipid levels are reportedly higher compared to the general population (30). Interestingly, low levels of low-density lipoproteins (LDL) are associated with COVID – 19 disease progression and mortality (31). It is unclear whether hyperlipidaemia has a protective role against severe disease and outcomes of HIV/SARS co-infection. On the other hand, the co-infection with Hepatitis B and/or C (9.7%) that we observed could increase COVID – 19 severity and mortality (32). A total of 129 (97.0%) patients were antiretroviral therapy (ART) experienced, and among those with a known HIV viral load, 113 (85.6%) were suppressed. One study did not report ART status (8). Given the high ART coverage in this population, our findings should be interpreted in the context of ART experienced, virologically suppressed PLHIV. Only 3 patients were explicitly reported as ART naïve (9,27,28). The clinical characteristics of HIV/SARS-CoV-2 co-infection among ART naïve PLHIV remain largely unknown. Nevertheless, antiretroviral therapy seems not to have profound effect on SARS-CoV-2, although it is protective against superimposed opportunistic infections (33).

## **Laboratory abnormalities**

The median/mean most recent CD4 count (range) was 298 – 670 cells/mm<sup>3</sup> (n = 107) (7,10,11,13). Studies reported elevated fibrinogen levels (12,27), C-reactive protein (7,9,12,14,18), D-dimers (9), lactate dehydrogenase (7,9,12) and liver enzymes (14,15,27) among individual patients. Thrombopenia (9,12), lymphopenia (9,12,14,28), higher lymphocyte count than HIV negative persons (7) and normal procalcitonin levels (7,9,12,14,25,27) were also reported. The counts were too few to derive meaningful interpretations.

### **Radiological imaging abnormalities**

CT and X-ray abnormalities were observed among 46 (54.1%) patients (7,9,10,14,22,23,25). This could be an underestimate since 56.5% of these were by X-ray, which has a low sensitivity among patients with COVID – 19 (34). Similar to studies among HIV negative SARS-CoV-2 cases (35), bilateral lung involvement was the commonest pattern.

### **Disease severity and drugs used in the management of HIV/SARS-CoV-2 co-infection**

Antibiotics, hydroxychloroquine, and lopinavir/ritonavir (as COVID-19 therapy, not ART) were prescribed for 27 (29.3%), 20 (21.7%), and 16 (17.4%) patients respectively. Treatments were not reported for 54 patients (8,11,13). Although the optimal treatment for COVID – 19 in HIV/SARS-CoV-2 co-infection is unknown, the safety and efficacy of lopinavir/ritonavir, hydroxychloroquine and antibiotics are still not well established (36). Randomised controlled trials are needed to determine the optimal ART among PLHIV with SARS-CoV-2. Disease severity was reported by 7 studies (9–11,13–15,25), and majority had mild disease (56.0%). Further, 80 (58.0%) of the HIV/SARS-CoV-2 cases were hospitalised. In contrast, 85.3% of inpatients with COVID -19 had moderate or severe disease in China (37). One study (13) did not report whether the patients were hospitalised or not. Table 2 shows other clinical features of HIV/SARS-CoV-2 co-infection.

### **Outcomes of HIV/SARS-CoV-2 co-infection**

The length of hospital stay ranged from 1 – 24 days (7,9,15,18,25,27,28). Among patients with a known outcome, 120 (88.9%) recovered whereas 11.1% died. The pooled mortality, from 6 studies (7,8,10–13), was 9% (95% CI: 3.0 – 15.0,  $I^2 = 25.6\%$ ,  $p = 0.24$ ) (figure 3), well within the range of 3.5 – 13.9% reported elsewhere (38,39). The high recovery observed among HIV/SARS-CoV-2 co-infected patient could be explained by many factors. As described above, the population was mostly <65 years of age with mostly mild disease. The possible protective role of hyperlipidaemia needs to be evaluated as well. Another hypothesis to explain the high recovery rate is that the impaired T-cell responses in HIV infection may be protective against severe lung inflammation (40). Okoh, *et al.*, (8) also found HIV infection to have a survival benefit among minority populations with COVID – 19.

There are key limitations of our study. First, the findings are not generalizable to low resource settings where the highest burden of HIV is found. Also, the majority of the studies reviewed were case reports and case series which inherently have bias. Additionally, the sample size is small and inferences cannot be made with certainty. Lastly, most of the patients in these studies were inpatients and therefore the reported severity of COVID -19 may not be accurate for the entire population of PLHIV. Larger studies are still needed to characterise the HIV/SARS-CoV-2 co-infection. Nevertheless, we have provided a preliminary but comprehensive synthesis of the current literature on HIV/SARS-CoV-2 co-infection.

## **CONCLUSION**

The prevalence of the HIV/SARS-CoV-2 co-infection is low. The clinical characteristics and outcomes of COVID – 19 among ART-experienced PLHIV and HIV negative individuals are comparable.

## **TRANSPERANCY DECLARATIONS**

### **Conflict of interest.**

The authors do have any conflict of interest to declare.

### **Source of funding:**

None

### **Access to data:**

Datasets used in this analysis are available from the corresponding author upon reasonable request

### **Acknowledgements:**

We appreciate all frontline healthcare workers taking care of COVID – 19 patients.

### **Author contribution**

**JBB** – Conception, design of the study, data acquisition, formal analysis, interpretation of data, drafting and revising article and final approval.

**RO** – Data acquisition, formal analysis, interpretation of data, revising article and final approval.

**CA** – Interpretation of data, revising article and final approval.

**JN** – Interpretation of data, revising article and final approval.

**LR** – Data acquisition, interpretation of data, revising article and final approval.

**FB** – Data acquisition, formal analysis, interpretation of data, revising article and final approval.

**JN** – Interpretation of data, revising article and final approval.

### **REFERENCES**

1. World Health Organisation. Coronavirus disease (COVID) Situation report - 129. 2020 May 28;
2. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis.* 2020 May 1;94:91–5.
3. UNAIDS U. Factsheet: global AIDS update. 2019. 2019;
4. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin Infect Dis Off Publ Infect Dis*

- Soc Am [Internet]. 2020 Mar 12 [cited 2020 May 26]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108125/>
5. Patel P, Rose CE, Collins PY, Nuche-Berenguer B, Sahasrabudde VV, Peprah E, et al. Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis. *AIDS Lond Engl*. 2018 01;32 Suppl 1:S5–20.
  6. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
  7. Karmen-Tuohy S, Carlucci PM, Zacharioudakis IM, Zervou FN, Rebick G, Klein E, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. *medRxiv*. 2020 May 12;2020.05.07.20094797.
  8. Okoh AK, Sossou C, Dangayach, Meledathu S, Oluwakemi P, Raczek C, et al. Coronavirus Disease 19 in Minority Populations of Newark, New Jersey. 2020 May 18 [cited 2020 May 26]; Available from: <https://europepmc.org/article/ppr/ppr164165>
  9. Blanco JL, Ambrosioni J, Garcia F, Martínez E, Soriano A, Mallolas J, et al. COVID-19 in patients with HIV: clinical case series. *Lancet HIV [Internet]*. 2020 Apr 15 [cited 2020 May 5];0(0). Available from: [https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018\(20\)30111-9/abstract](https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30111-9/abstract)
  10. Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D, et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. *Clin Infect Dis [Internet]*. [cited 2020 May 26]; Available from: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa579/5837155>
  11. Härter G, Spinner CD, Roider J, Bickel M, Krznaric I, Grunwald S, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. *Infection*. 2020 May 11;
  12. Aydin OA, Karaosmanoglu HK, Yasar KK. HIV/SARS-CoV-2 co-infected patients in Istanbul, Turkey. *J Med Virol [Internet]*. [cited 2020 May 8];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25955>
  13. Guo W, Ming F, Dong Y, Zhang Q, Zhang X, Mo P, et al. A Survey for COVID-19 Among HIV/AIDS Patients in Two Districts of Wuhan, China [Internet]. Rochester, NY: Social Science Research Network; 2020 Mar [cited 2020 May 26]. Report No.: ID 3550029. Available from: <https://papers.ssrn.com/abstract=3550029>
  14. Parker A, Shaw J, Karamchand S, Lahri S, Schrueder N, Chothia M-Y, et al. HIV and SARS-CoV-2 co-infection: The diagnostic challenges of dual pandemics. *S Afr Med J [Internet]*. 2020 Apr 30 [cited 2020 May 26];110(6). Available from: <http://www.samj.org.za/index.php/samj/article/view/12940>
  15. Baluku JB, Mwebaza S, Ingabire G, Nsereko C, Muwanga M. HIV and SARS-CoV-2 co-infection: A case report from Uganda. *J Med Virol [Internet]*. [cited 2020 May 26];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26044>
  16. Kharsany ABM, Karim QA. HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. *Open AIDS J*. 2016 Apr 8;10:34–48.

17. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic Population. *N Engl J Med*. 2020 Apr 14;0(0):null.
18. Zhao J, Liao X, Wang H, Wei L, Xing M, Liu L, et al. Early Virus Clearance and Delayed Antibody Response in a Case of Coronavirus Disease 2019 (COVID-19) With a History of Coinfection With Human Immunodeficiency Virus Type 1 and Hepatitis C Virus. *Clin Infect Dis [Internet]*. [cited 2020 May 5]; Available from: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa408/5818121>
19. Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and therapeutic treatments for viral diseases. *BioEssays News Rev Mol Cell Dev Biol*. 2012 Dec;34(12):1050–9.
20. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *J Infect [Internet]*. 2020 Apr 23 [cited 2020 May 28]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177098/>
21. Drain PK, Garrett N. SARS-CoV-2 pandemic expanding in sub-Saharan Africa: Considerations for COVID-19 in people living with HIV. *EClinicalMedicine [Internet]*. 2020 Apr 21 [cited 2020 May 26];0(0). Available from: [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(20\)30086-9/abstract](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30086-9/abstract)
22. Benkovic S, Kim M, Sin E. 4 Cases: HIV and SARS-CoV-2 Co-infection in patients from Long Island, New York. *J Med Virol [Internet]*. [cited 2020 May 26];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26029>
23. Riva A, Conti F, Bernacchia D, Pezzati L, Sollima S, Merli S, et al. Darunavir does not prevent SARS-CoV-2 infection in HIV patients. *Pharmacol Res*. 2020 Jul;157:104826.
24. Chen J, Cheng X, Wang R, Zeng X. Computed Tomography Imaging of an HIV-infected Patient with Coronavirus Disease 2019 (COVID-19). *J Med Virol [Internet]*. [cited 2020 May 8];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25879>
25. Louisa SJ, Lin Serene WX, Gollamudi S. A case of HIV and SARS-CoV-2 co-infection in Singapore. *J Acquir Immune Defic Syndr 1999*. 2020 May 11;
26. Li L, Huang T, Wang Y, Wang Z, Liang Y, Huang T, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol*. 2020;92(6):577–83.
27. Wang M, Luo L, Bu H, Xia H. One case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a low CD4+ T-cell count. *Int J Infect Dis*. 2020 Jul 1;96:148–50.
28. Zhu F, Cao Y, Xu S, Zhou M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. *J Med Virol*. 2020;92(6):529–30.
29. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J [Internet]*. 2020 Jan 1 [cited 2020 May 28]; Available from: <https://erj.ersjournals.com/content/early/2020/03/17/13993003.00547-2020>

30. Touloumi G, Kalpourtzi N, Papastamopoulos V, Papparizos V, Adamis G, Antoniadou A, et al. Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece. *PLOS ONE*. 2020 Mar 30;15(3):e0230730.
31. Fan J, Wang H, Ye G, Cao X, Xu X, Tan W, et al. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. *Metabolism* [Internet]. 2020 Apr 19 [cited 2020 May 29]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166305/>
32. Chen X, Jiang Q, Ma Z, Ling J, Hu W, Cao Q, et al. Clinical Characteristics of Hospitalized Patients with SARS-CoV-2 and Hepatitis B virus Co-infection. *medRxiv*. 2020 Mar 30;2020.03.23.20040733.
33. Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. *J Int AIDS Soc*. 2020;23(4):e25489.
34. Weinstock MB, Echenique A, DABR JWR, Leib A, ILLUZZI FA. Chest X-Ray Findings in 636 Ambulatory Patients with COVID-19 Presenting to an Urgent Care Center: A Normal Chest X-Ray Is no Guarantee. *J Urgent Care Med* 14 7. 2020;13–8.
35. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* [Internet]. 2020 Feb 28 [cited 2020 May 29]; Available from: <https://www.nejm.org/doi/10.1056/NEJMoa2002032>
36. Wu R, Wang L, Kuo H-CD, Shannar A, Peter R, Chou PJ, et al. An Update on Current Therapeutic Drugs Treating COVID-19. *Curr Pharmacol Rep* [Internet]. 2020 May 11 [cited 2020 May 28]; Available from: <https://doi.org/10.1007/s40495-020-00216-7>
37. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. *Clin Microbiol Infect* [Internet]. 2020 Apr 15 [cited 2020 May 5];0(0). Available from: [https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X\(20\)30217-2/abstract](https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30217-2/abstract)
38. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. *J Infect* [Internet]. 2020 Apr 10 [cited 2020 May 5]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151416/>
39. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Med Infect Dis* [Internet]. 2020 Mar 13 [cited 2020 May 5]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102608/>
40. Romanelli A, Mascolo S. Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis. *Am J Transplant* [Internet]. [cited 2020 May 28];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.15905>

**Table 1: Characteristics of studies**

<b>Study</b>	<b>Design</b>	<b>Country</b>	<b>No. of patients</b>
<b>Gervasoni, et al. (10)<sup>†</sup></b>	Retrospective cohort	Italy	47
<b>Härter, et al. (11)</b>	Multicentre case series	Germany	33
<b>Karmen-Tuohy, et al. (7)</b>	Retrospective matched cohort	USA	21
<b>Okoh, et al. (8)</b>	Retrospective cohort	USA	13
<b>Guo, et al. (13)</b>	Survey	China	8
<b>Blanco, et al. (9)</b>	Case series	Spain	5
<b>Benkovic, et al. (22)</b>	Case series	USA	4
<b>Aydin, et al. (12)</b>	Case series	Turkey	4
<b>Riva, et al. (23)</b>	Case series	Italy	3
<b>Wang, et al. (27)</b>	Case report	China	1
<b>Drain, et al. (21)</b>	Commentary	USA	1
<b>Chen et al. (24)</b>	Case report	China	1
<b>Baluku et al. (15)</b>	Case report	Uganda	1
<b>Parker et al. (14)</b>	Case report	South Africa	1
<b>Louisa et al. (25)</b>	Case report	Singapore	1
<b>Zhu et al. (28)</b>	Case report	China	1
<b>Zhao et al. (18)</b>	Case report	China	1

<sup>†</sup>includes 19 patients with probable SARS-CoV-2 but were not tested

**Table 2: Clinical features of HIV and SARS-CoV-2 co-infection**

<b>Clinical characteristics</b>	<b>n (%)</b>
<b>Other comorbid conditions</b>	
At least one condition	62 (65.3)
Hypertension	38 (26.4)
Hyperlipidemia	22 (15.3)
Diabetes	14 (9.7)
Hepatitis B or C	14 (9.7)
Obstructive airway disease	14 (9.7)
Renal disease	10 (6.9)
Other comorbid condition <sup>§</sup>	33 (22.9)
<b>Symptoms</b>	
Duration before presentation, range (days) <sup>†</sup>	1 – 14
Fever	76 (73.8)
Cough	59 (57.3)
Shortness of breath	13 (12.6)
Myalgia	13 (12.6)
Headache	12 (11.7)
Diarrhoea	11 (10.7)
Other symptoms <sup>§</sup>	28 (27.2)
<b>Disease severity</b>	
Mild	28 (56.0)
Moderate	8 (16.0)
Severe	12 (24.0)
Critical	2 (4.0)
<b>Computed tomography and X-ray abnormalities</b>	
Abnormalities present	46 (54.1)

---

Bilateral involvement	28 (82.4)
Unilateral	6 (17.6)
<b>Pattern</b>	
Interstitial pattern	9 (32.1)
Ground glass appearance	7 (25.0)
Unknown pattern	12 (42.9)
<b>Drugs used in treatment</b>	
Antibiotics*	27 (29.3)
Hydroxychloroquine	20 (21.7)
Lopinavir/ritonavir	16 (17.4)
Tocilizumab	5 (5.4)
Ostelmiriv	5 (5.4)
Remdesivir	2 (2.2)
Others <sup>#</sup>	17 (18.5)

<sup>†</sup>For one patient, symptom duration was 33 days (**27**), <sup>§</sup>includes anosmia, chest pain, anorexia, fatigue, sinusitis, sore throat; <sup>¶</sup>includes unspecified cardiovascular disease, obesity, smoking, organ transplant, atrial fibrillation, coronary artery disease, syphilis, peripheral artery disease, cancer, epilepsy, gastritis, bipolar affective disease and hypothyroidism; \* include macrolides, quinolones, cotrimoxazole, meropenem, cephalosporin, linezolid and amoxicillin-clavulinate; <sup>#</sup>include corticosteroids, gamma-globulin and interferon.

---




Figure 1: Study flow diagram




Figure 2: Pooled prevalence of HIV among SARS-CoV-2 cases




Figure 3: Pooled mortality among HIV/SARS-CoV-2 co-infection cases

## APPENDIX1: SEARCH STRATEGY

#	Database	Search term	Results
1	Medline	(HIV).ti,ab	303069
2	Medline	exp HIV/	98023
3	Medline	("Human Immunodeficiency Virus*").ti,ab	85715
4	Medline	(1 OR 2 OR 3)	329236
5	Medline	("COVID 19" OR "SARS Cov 2" OR "coronavirus disease 2019" OR "novel coronavirus 2019" OR "Severe acute respiratory syndrome coronavirus 2" OR "2019-nCoV").ti,ab	14562
6	Medline	CORONAVIRUS/	2326
7	Medline	("2019" OR "covid").ti,ab	65659
8	Medline	(6 AND 7)	424
9	Medline	(5 OR 8)	14576
10	Medline	(4 AND 9)	99
12	Medline	("co infection" OR "coinfection").ti,ab	18906
13	Medline	COINFECTION/	10356
14	Medline	(12 OR 13)	24617
15	Medline	(10 AND 14)	9
16	Medline	15 [Document type Review]	0
17	EMBASE	(HIV).ti,ab	391846
18	EMBASE	exp HIV/	193975
19	EMBASE	("Human Immunodeficiency	93998

		Virus*).ti,ab	
20	EMBASE	(17 OR 18 OR 19)	434524
21	EMBASE	("COVID 19" OR "SARS Cov 2" OR "coronavirus disease 2019" OR "novel coronavirus 2019" OR "Severe acute respiratory syndrome coronavirus 2" OR "2019-nCoV").ti,ab	11517
22	EMBASE	CORONAVIRUS/	6805
23	EMBASE	("2019" OR "covid").ti,ab	91127
24	EMBASE	(22 AND 23)	20
25	EMBASE	(21 OR 24)	11524
26	EMBASE	(20 AND 25)	93
27	EMBASE	("co infection" OR "coinfection").ti,ab	27011
28	EMBASE	COINFECTION/	15544
29	EMBASE	(27 OR 28)	35221
30	EMBASE	(26 AND 29)	8
31	EMBASE	30 [Publication types Review]	0